GHRP-2 vs GHRP-6 vs Ipamorelin: Which GHRP Is Best?

How They Work

GHRP-2, GHRP-6, and ipamorelin are all growth hormone releasing peptides (GHRPs). They share a common mechanism: they bind to the growth hormone secretagogue receptor (GHS-R1a), the same receptor that ghrelin targets, on the pituitary gland. When they bind, the pituitary responds with a burst of growth hormone. All three trigger pulsatile GH release, meaning they produce distinct spikes that rise and fall, closely mimicking the body's natural GH rhythm.

But that is where the similarities end. These three peptides represent three generations of GHRP development. Each generation refined the previous one, trading raw potency for increasing selectivity. Understanding those generational differences is the key to understanding which one does what.

GHRP-6: The First Generation. GHRP-6 was one of the earliest synthetic GHRPs studied in humans. It binds aggressively to the ghrelin receptor, triggering a strong GH pulse from the pituitary. But its receptor binding is not selective. GHRP-6 activates the ghrelin receptor broadly, which means it also triggers powerful hunger signaling in the hypothalamus. Users typically experience an intense appetite spike within 20 minutes of injection that can last up to an hour. Beyond hunger, GHRP-6 also stimulates the adrenal axis, leading to measurable increases in cortisol and ACTH. It can elevate prolactin as well. These off-target effects are the direct result of its broad receptor activation profile.

GHRP-2: The Second Generation. GHRP-2 was developed as an improvement on GHRP-6. It produces a stronger GH release per dose than GHRP-6, making it one of the most potent GHRPs studied. It still activates the ghrelin receptor broadly enough to cause some appetite stimulation, but significantly less than GHRP-6. The hunger effect is mild and manageable for most users. GHRP-2 also raises cortisol and prolactin, but to a lesser degree than GHRP-6, particularly at standard dosing ranges. It sits in the middle of the selectivity spectrum: more potent than GHRP-6 for GH release, cleaner on side effects, but still not fully selective.

Ipamorelin: The Third Generation. Ipamorelin was designed specifically to solve the selectivity problem. The foundational study by Raun et al. (1998, PMID: 9784065) established ipamorelin as the first truly selective growth hormone secretagogue. It binds the GHS-R1a receptor in a way that stimulates GH release without triggering the downstream cortisol, prolactin, or ACTH increases that GHRP-6 and GHRP-2 cause. It produces no meaningful hunger spike. The GH release is dose-dependent and clean. The trade-off is that ipamorelin's peak GH output is somewhat lower than GHRP-2's at equivalent doses. It gives up a margin of raw potency in exchange for a dramatically cleaner hormonal profile.

All three peptides also suppress somatostatin, the hormone that acts as a brake on GH release. By reducing that brake while simultaneously pressing the accelerator (ghrelin receptor activation), GHRPs produce a stronger GH pulse than natural ghrelin alone. This dual action is part of why GHRPs are effective secretagogues even in older adults whose natural GH output has declined significantly.

The core distinction across these three peptides is the potency-selectivity trade-off. GHRP-6 is a blunt instrument: strong GH release, but it activates everything along the way. GHRP-2 sharpened that instrument: stronger GH release with fewer off-target effects. Ipamorelin is a scalpel: clean, selective GH release with essentially no hormonal collateral damage. Each generation sacrificed some breadth of effect to gain precision. Which matters more depends entirely on the user's goals and tolerance for side effects.

What the Research Shows

The published research on GHRPs spans several decades, beginning in the 1980s with early hexapeptide secretagogues and continuing through the development of ipamorelin in the late 1990s. The literature is strongest on pharmacokinetics, dose-response relationships, and hormonal selectivity. Large-scale clinical outcome trials for any of these three peptides do not exist.

GHRP-6: Strong Release, Broad Activation. GHRP-6 was among the first synthetic GHRPs studied in clinical settings. Bowers et al. published foundational work through the 1980s and 1990s demonstrating that GHRP-6 reliably stimulates GH release in a dose-dependent manner in both healthy subjects and GH-deficient patients (PMID: 2117684). Studies consistently showed that GHRP-6 at standard doses (1-2 mcg/kg IV or 100-200 mcg subcutaneous) produces GH peaks of 20-50 ng/mL, depending on dose and individual response. However, the same studies documented concurrent increases in cortisol (20-50% above baseline), ACTH, and prolactin. Bowers' work also established the synergistic principle: when GHRP-6 was co-administered with GHRH, the resulting GH release was significantly greater than the sum of either compound alone. This GHRP+GHRH synergy principle later became the foundation for ipamorelin + CJC-1295 stacking protocols.

GHRP-2: The Potency Leader. Comparative studies in the late 1990s and early 2000s positioned GHRP-2 as the most potent GHRP for acute GH release. A study by Pihoker et al. (1995, PMID: 7665540) demonstrated that GHRP-2 produced robust GH responses in children and adults, with dose-dependent increases that exceeded GHRP-6 at comparable doses. GHRP-2 at 1 mcg/kg produced GH peaks in the range of 30-60 ng/mL in healthy adults. Importantly, while GHRP-2 did elevate cortisol and prolactin, the magnitude was consistently lower than what GHRP-6 produced at equivalent GH-releasing doses. A head-to-head comparison published by Bowers (PMID: 9519948) confirmed that GHRP-2 achieved superior GH release with a somewhat improved side effect profile relative to GHRP-6, though it was not fully selective.

Ipamorelin: Selectivity Proven. The Raun et al. study (1998, PMID: 9784065) remains the landmark paper for ipamorelin. Using a swine model, the researchers demonstrated that ipamorelin produced dose-dependent GH release that increased linearly with dose, while cortisol, ACTH, prolactin, FSH, and LH all remained at baseline levels. This was the first time a GHRP had achieved GH stimulation without any measurable off-target hormonal effects. Subsequent human pharmacokinetic studies confirmed this selectivity profile in clinical settings. A study by Gobburu et al. (1999, PMID: 10434620) developed a pharmacokinetic-pharmacodynamic model for ipamorelin in humans, showing predictable dose-dependent GH release with a half-life suitable for once or twice daily dosing. The GH peaks produced by ipamorelin (typically 15-40 ng/mL at standard doses) were somewhat lower than GHRP-2's maximal output, but the absence of cortisol and prolactin elevation made it the clear winner on tolerability.

The Generational Pattern in the Data. When the three peptides are viewed together, the research tells a clear story. GHRP-6 and GHRP-2 are potent but pharmacologically noisy. They raise GH effectively, but they also raise hormones you do not want elevated on a chronic basis. Ipamorelin is pharmacologically quiet. It raises GH and nothing else. The data does not suggest that ipamorelin is a weak secretagogue. It produces clinically meaningful GH elevation. It simply does not produce the maximal peak GH numbers that GHRP-2 can achieve. For most clinical applications, particularly in anti-aging and recovery contexts, the moderate-but-clean profile is preferred over the maximal-but-noisy one.

Limitations. None of these three peptides have completed Phase 3 clinical trials for any indication. The published evidence establishes pharmacology, not long-term outcomes. Body composition changes, recovery improvements, sleep quality gains, and anti-aging effects reported by users and clinicians have not been validated in randomized controlled trials. The mechanistic science is solid and spans decades. The outcome data remains anecdotal.

Side Effects and Tolerability

The side effect profiles of these three peptides diverge sharply, and those differences are the primary reason ipamorelin dominates modern clinical practice while GHRP-6 and GHRP-2 have faded in popularity.

Cortisol Elevation. GHRP-6 produces the most significant cortisol increase of the three. Studies show cortisol rises of 20-50% above baseline following standard GHRP-6 doses. Chronically elevated cortisol promotes visceral fat storage, breaks down muscle tissue, impairs sleep quality, suppresses immune function, and increases insulin resistance. For a peptide intended to improve body composition and recovery, cortisol elevation is directly counterproductive. GHRP-2 raises cortisol as well, but to a lesser degree, particularly at the lower end of its dosing range. Ipamorelin does not raise cortisol at any studied dose. The Raun 1998 data showed cortisol flatlined at baseline even at supraphysiological ipamorelin doses.

Prolactin Elevation. Both GHRP-6 and GHRP-2 can elevate prolactin levels. Elevated prolactin in men can suppress testosterone production, reduce libido, cause fatigue, and in prolonged cases contribute to gynecomastia. In women, it can disrupt menstrual cycles. The prolactin increases from GHRP-6 and GHRP-2 are generally mild at standard doses but become more pronounced at higher doses or with prolonged use. Ipamorelin does not elevate prolactin. This is one of the most clinically significant advantages of ipamorelin over its predecessors.

Appetite Stimulation. GHRP-6 is notorious for causing intense, sometimes overwhelming hunger within 15-30 minutes of injection. This occurs because GHRP-6 strongly activates ghrelin signaling in the hypothalamus, not just at the pituitary. For someone trying to lose body fat, this is a serious problem. For someone who is underweight, struggling to eat enough (such as during recovery from illness or in elderly patients with diminished appetite), this hunger effect can actually be therapeutic. GHRP-2 causes mild-to-moderate appetite stimulation. Most users describe it as noticeable but manageable. Ipamorelin causes no meaningful hunger increase. Its binding profile at the ghrelin receptor is selective enough to trigger pituitary GH release without activating hypothalamic hunger circuits.

Water Retention and Injection Site Effects. All three GHRPs can cause mild water retention, particularly in the first one to two weeks of use. This is a downstream effect of elevated GH, which increases sodium and water reabsorption in the kidneys. Temporary bloating, puffiness in the hands or face, and a two-to-four-pound increase in scale weight are common early effects that typically resolve as the body adjusts. Injection site reactions (redness, mild irritation, transient numbness) are occasionally reported with all three and are generally mild.

Practical Tolerability Ranking. In clinical practice, the tolerability hierarchy is clear. Ipamorelin is the most tolerable by a significant margin. No hunger spikes, no cortisol elevation, no prolactin concerns. GHRP-2 is the middle ground. Manageable hunger, mild hormonal perturbations at standard doses, and strong GH output. GHRP-6 is the least tolerable for chronic use. The intense hunger and more pronounced cortisol and prolactin effects make it poorly suited for long-term anti-aging or recovery protocols. Its primary use case is in situations where appetite stimulation is specifically desired.

None of these peptides are FDA-approved for human use. They are classified as research peptides. Manufacturing standards vary by supplier. Third-party certificates of analysis, physician supervision, and regular blood work (GH, IGF-1, cortisol, prolactin, fasting glucose, insulin) are strongly recommended for anyone using these compounds.

Cost, Access, and Practical Considerations

All three GHRPs occupy a similar price tier in the research peptide market. They are generally less expensive than newer or more complex peptides, but cost and access vary depending on supplier, form, and geography.

Pricing. GHRP-6 is typically the least expensive, often available at $15-30 per 5 mg vial from research peptide suppliers. GHRP-2 is slightly more, generally $20-40 per 5 mg vial. Ipamorelin tends to be the most expensive of the three, typically $30-60 per 5 mg vial, reflecting its status as the most in-demand GHRP in clinical practice. Pricing fluctuates based on supplier, quantity, and purity. At standard dosing of 200-300 mcg per injection, a single 5 mg vial provides roughly 16-25 doses, making all three relatively affordable compared to exogenous growth hormone, which can cost $500-1,500 or more per month.

Sourcing and Quality. Because none of these peptides are FDA-approved, they are not available through standard pharmacies. They are obtained through research peptide suppliers, compounding pharmacies (in jurisdictions where this is permitted), or anti-aging and peptide therapy clinics. Quality varies enormously across suppliers. Independent third-party testing (certificates of analysis showing purity, identity, and sterility) is the minimum standard for any supplier worth considering. Contamination, underdosing, and degraded product are real risks with unverified sources.

Reconstitution and Storage. All three peptides are supplied as lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before use. The process is identical for all three: inject bacteriostatic water into the vial, swirl gently (never shake), and store refrigerated at 2-8 degrees Celsius. Reconstituted peptides should be used within four to six weeks. Unreconstituted vials store well refrigerated for months. Heat, direct sunlight, and repeated freeze-thaw cycles degrade peptide bonds and reduce potency.

Administration. Standard administration for all three is subcutaneous injection, typically in the abdominal area. Insulin syringes (29-31 gauge, 0.5 mL) are standard. Injection frequency ranges from one to three times daily depending on the protocol. Timing matters: GHRPs are best taken on an empty stomach, as elevated blood sugar and insulin blunt the GH response. A minimum two-hour fast before injection and a 30-60 minute wait before eating afterward is generally recommended to preserve the GH pulse.

Availability Trends. The regulatory landscape for research peptides has tightened in recent years. Some suppliers have reduced or eliminated their GHRP offerings. Ipamorelin remains the most widely available of the three due to strong clinical demand. GHRP-2 and GHRP-6 are still obtainable but may require more searching as the market consolidates around newer and more selective compounds. Anyone considering these peptides should verify current availability and legality in their jurisdiction, as regulations differ by country and change frequently.

Stacking Considerations. All three GHRPs are commonly stacked with a GHRH analog, most often CJC-1295 without DAC (Mod GRF 1-29), to exploit the well-documented GHRP+GHRH synergy. The choice of which GHRP to pair with CJC-1295 depends on the user's goals and tolerance profile. Ipamorelin + CJC-1295 is the most widely recommended combination in clinical practice. GHRP-2 + CJC-1295 is preferred by users seeking maximum GH output with acceptable side effects. GHRP-6 + CJC-1295 is occasionally used in bulking contexts where appetite stimulation is a feature, not a bug.

The Bottom Line

GHRP-2, GHRP-6, and ipamorelin are three generations of the same idea: stimulate the pituitary to release more growth hormone by targeting the ghrelin receptor. Each generation improved on the last, and the improvements followed a consistent direction. Less hormonal noise. Fewer off-target effects. Greater selectivity.

GHRP-6 is the first generation. It works, but it hits hard and wide. Strong GH release paired with intense hunger, cortisol elevation, and prolactin increases. Its best remaining use case is for individuals who specifically want appetite stimulation, such as underweight patients, people recovering from illness, or hardgainers who struggle to eat enough to support muscle growth. For everyone else, its side effect profile makes it a poor choice for chronic use.

GHRP-2 is the second generation. It produces the strongest acute GH release of the three and cleans up the side effect profile relative to GHRP-6. The hunger is manageable. The cortisol and prolactin increases are mild at standard doses. It is a reasonable choice for someone who prioritizes raw GH output and can tolerate mild off-target effects. It occupies the middle ground between potency and selectivity.

Ipamorelin is the third generation and the clear default for most users. It sacrifices a margin of peak GH potency in exchange for a dramatically cleaner profile. No cortisol increase. No prolactin increase. No hunger spike. For recovery, sleep quality, anti-aging, and general body composition goals, that selectivity matters more than squeezing out a marginally higher GH peak. This is why ipamorelin became the standard GHRP in clinical peptide therapy.

The trade-off is real but straightforward: potency vs. selectivity. More is not always better when the "more" includes hormones you do not want elevated chronically. For the vast majority of use cases, the selectivity advantage of ipamorelin outweighs the modest potency advantage of GHRP-2 or GHRP-6.

None of these peptides are FDA-approved for human use. Long-term clinical outcome data is limited for all three. The pharmacological data is well-established and spans decades of published research. But pharmacology is not the same as clinical proof of long-term benefit. Anyone using these peptides should do so under medical supervision with baseline and ongoing blood work monitoring for GH, IGF-1, cortisol, prolactin, fasting glucose, and insulin. The science supports the mechanism. Responsible use requires acknowledging what that science does and does not yet prove.